winning10bagger, I disagree, have previously posted estimates...

winning10bagger, I disagree, have previously posted estimates based on a conservative market size across multiple indications.

Even with Ovarian alone, 10% market share, CVac would earn more profit in one year than the current market cap.

5% of MUC-1 market in the US alone (7 cancers, 990,000 patients p.a) = $2.3B gross profit.

That would be an EPS of $2 in a year (assuming limited dilution)
You can work out what P/E ratio to attribute to bios, but let's say 10 to be conservative. = $20 sp

The remaining major markets are additional.

Now, realise this is all hypothetical and that the likelihood of this all happening relies on almost everything going Prima's way. However, this isn't a mining company. 1000, 2000 or 5000% returns aren't unheard of developing in biotechs reaching commercialisation with successful treatments.


Now whether the potential will become reality is something everyone has to make their bet on, also whether they can wait the years it would take.

There are many things that stand in the way of that potential, and even if we did gain approval, there's no guarantee the market will pay the asking price, or competition won't steal market share. It seems the risks are too high for many investors, so the SP is declining. To the point that marco is interested again, it would seem.